{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:32:44Z","timestamp":1782315164437,"version":"3.54.5"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["26678"],"award-info":[{"award-number":["26678"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["26678"],"award-info":[{"award-number":["26678"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FRN-408093"],"award-info":[{"award-number":["FRN-408093"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canada Research Chair in Pharmacogenomics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2023,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Naturally occurring germline gene deletions (KO) represent a unique setting to interrogate gene functions. Complete deletions and differential expression of the human glycosyltransferase <jats:italic>UGT2B17<\/jats:italic> and <jats:italic>UGT2B28<\/jats:italic> genes are linked to prostate cancer (PCa) risk and progression, leukaemia, autoimmune and other diseases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The systemic metabolic consequences of UGT deficiencies were examined using untargeted and targeted mass spectrometry-based metabolomics profiling of carefully matched, treatment-naive PCa cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Each UGT KO differentially affected over 5% of the 1545 measured metabolites, with divergent metabolic perturbations influencing the same pathways. Several of the perturbed metabolites are known to promote PCa growth, invasion and metastasis, including steroids, ceramides and kynurenine. In <jats:italic>UGT2B17<\/jats:italic> KO, reduced levels of inactive steroid-glucuronides were compensated by sulfated derivatives that constitute circulating steroid reservoirs. <jats:italic>UGT2B28<\/jats:italic> KO presented remarkably lower levels of oxylipins paralleled by reduced inflammatory mediators, but higher ceramides unveiled as substrates of the enzyme in PCa cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The distinctive and broad metabolic rewiring caused by UGT KO reinforces the need to examine their unique and divergent functions in PCa biology.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-022-02040-w","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T17:13:22Z","timestamp":1667927602000},"page":"285-296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer"],"prefix":"10.1038","volume":"128","author":[{"given":"Mich\u00e8le","family":"Rouleau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Nguyen Van Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Turcotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4811-0308","authenticated-orcid":false,"given":"Louis","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armen","family":"Aprikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2986-5617","authenticated-orcid":false,"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Carmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5986-3458","authenticated-orcid":false,"given":"Eric","family":"L\u00e9vesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1113-1212","authenticated-orcid":false,"given":"Chantal","family":"Guillemette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"2040_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.molmed.2016.02.006","volume":"22","author":"VM Narasimhan","year":"2016","unstructured":"Narasimhan VM, Xue Y, Tyler-Smith C. Human knockout carriers: dead, diseased, healthy, or improved? Trends Mol Med. 2016;22:341\u201351.","journal-title":"Trends Mol Med"},{"key":"2040_CR2","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264\u201372.","journal-title":"N Engl J Med"},{"key":"2040_CR3","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1126\/science.1161524","volume":"322","author":"TI Pollin","year":"2008","unstructured":"Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702\u20135.","journal-title":"Science"},{"key":"2040_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12360","volume":"7","author":"EP Rhee","year":"2016","unstructured":"Rhee EP, Yang Q, Yu B, Liu X, Cheng S, Deik A, et al. An exome array study of the plasma metabolome. Nat Commun. 2016;7:12360.","journal-title":"Nat Commun"},{"key":"2040_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/ng1696","volume":"38","author":"SA McCarroll","year":"2006","unstructured":"McCarroll SA, Hadnott TN, Perry GH, Sabeti PC, Zody MC, Barrett JC, et al. Common deletion polymorphisms in the human genome. Nat Genet. 2006;38:86\u201392.","journal-title":"Nat Genet"},{"key":"2040_CR6","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/gim.2017.156","volume":"20","author":"M Santos","year":"2018","unstructured":"Santos M, Niemi M, Hiratsuka M, Kumondai M, Ingelman-Sundberg M, Lauschke VM, et al. Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. Genet Med. 2018;20:622\u20139.","journal-title":"Genet Med"},{"key":"2040_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ajhg.2008.08.004","volume":"83","author":"Y Xue","year":"2008","unstructured":"Xue Y, Sun D, Daly A, Yang F, Zhou X, Zhao M, et al. Adaptive evolution of UGT2B17 copy-number variation. Am J Hum Genet. 2008;83:337\u201346.","journal-title":"Am J Hum Genet"},{"key":"2040_CR8","doi-asserted-by":"publisher","first-page":"D884","DOI":"10.1093\/nar\/gkaa942","volume":"49","author":"KL Howe","year":"2021","unstructured":"Howe KL, Achuthan P, Allen J, Allen J, Alvarez-Jarreta J, Amode MR, et al. Ensembl 2021. Nucleic Acids Res. 2021;49:D884\u2013D891.","journal-title":"Nucleic Acids Res"},{"key":"2040_CR9","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1002\/cncr.28009","volume":"119","author":"AY Angstadt","year":"2013","unstructured":"Angstadt AY, Berg A, Zhu J, Miller P, Hartman TJ, Lesko SM, et al. The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk. Cancer. 2013;119:2477\u201385.","journal-title":"Cancer"},{"key":"2040_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.eururo.2015.06.054","volume":"69","author":"A Belledant","year":"2016","unstructured":"Belledant A, Hovington H, Garcia L, Caron P, Brisson H, Villeneuve L, et al. The UGT2B28 sex-steroid inactivation pathway is a regulator of steroidogenesis and modifies the risk of prostate cancer progression. Eur Urol. 2016;69:601\u20139.","journal-title":"Eur Urol"},{"key":"2040_CR11","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.3324\/haematol.2015.136440","volume":"101","author":"S Bhoi","year":"2016","unstructured":"Bhoi S, Baliakas P, Cortese D, Mattsson M, Engvall M, Smedby KE, et al. UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia? Haematologica. 2016;101:e63\u201365.","journal-title":"Haematologica"},{"key":"2040_CR12","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2012-08-447359","volume":"121","author":"M Gruber","year":"2013","unstructured":"Gruber M, Bellemare J, Hoermann G, Gleiss A, Porpaczy E, Bilban M, et al. Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. Blood. 2013;121:1175\u201383.","journal-title":"Blood"},{"key":"2040_CR13","doi-asserted-by":"publisher","first-page":"E1550","DOI":"10.1210\/jc.2011-1049","volume":"96","author":"G Nadeau","year":"2011","unstructured":"Nadeau G, Bellemare J, Audet-Walsh E, Flageole C, Huang SP, Bao BY, et al. Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. J Clin Endocrinol Metab. 2011;96:E1550\u20131557.","journal-title":"J Clin Endocrinol Metab"},{"key":"2040_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1158\/1055-9965.EPI-09-1018","volume":"19","author":"SR Setlur","year":"2010","unstructured":"Setlur SR, Chen CX, Hossain RR, Ha JS, Van Doren VE, Stenzel B, et al. Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. Cancer Epidemiol Biomark Prev. 2010;19:229\u201339.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2040_CR15","first-page":"1716","volume":"19","author":"HM Albertsen","year":"2019","unstructured":"Albertsen HM, Matalliotaki C, Matalliotakis M, Zervou MI, Matalliotakis I, Spandidos DA, et al. Whole exome sequencing identifies hemizygous deletions in the UGT2B28 and USP17L2 genes in a three generation family with endometriosis. Mol Med Rep. 2019;19:1716\u201320.","journal-title":"Mol Med Rep"},{"key":"2040_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-12-111","volume":"12","author":"I Bronstad","year":"2011","unstructured":"Bronstad I, Wolff AS, Lovas K, Knappskog PM, Husebye ES. Genome-wide copy number variation (CNV) in patients with autoimmune Addison\u2019s disease. BMC Med Genet. 2011;12:111.","journal-title":"BMC Med Genet"},{"key":"2040_CR17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.cdp.2007.07.005","volume":"31","author":"CJ Gallagher","year":"2007","unstructured":"Gallagher CJ, Kadlubar FF, Muscat JE, Ambrosone CB, Lang NP, Lazarus P. The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians. Cancer Detect Prev. 2007;31:310\u20135.","journal-title":"Cancer Detect Prev"},{"key":"2040_CR18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s00198-011-1662-6","volume":"23","author":"S Giroux","year":"2012","unstructured":"Giroux S, Bussieres J, Bureau A, Rousseau F. UGT2B17 gene deletion associated with an increase in bone mineral density similar to the effect of hormone replacement in postmenopausal women. Osteoporos Int. 2012;23:1163\u201370.","journal-title":"Osteoporos Int"},{"key":"2040_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/sj.tpj.6500449","volume":"8","author":"AH Karypidis","year":"2008","unstructured":"Karypidis AH, Olsson M, Andersson SO, Rane A, Ekstrom L. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. Pharmacogenomics J. 2008;8:147\u201351.","journal-title":"Pharmacogenomics J"},{"key":"2040_CR20","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/s41416-020-0749-2","volume":"122","author":"E Levesque","year":"2020","unstructured":"Levesque E, Labriet A, Hovington H, Allain EP, Melo-Garcia L, Rouleau M, et al. Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression. Br J Cancer. 2020;122:1068\u201376.","journal-title":"Br J Cancer"},{"key":"2040_CR21","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/ng.490","volume":"41","author":"SA McCarroll","year":"2009","unstructured":"McCarroll SA, Bradner JE, Turpeinen H, Volin L, Martin PJ, Chilewski SD, et al. Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet. 2009;41:1341\u20134.","journal-title":"Nat Genet"},{"key":"2040_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.clim.2019.07.010","volume":"207","author":"Q Shen","year":"2019","unstructured":"Shen Q, Lee K, Han SK, Ahn HJ, Kim S, Lee JH. Variants at potential loci associated with Sjogren\u2019s syndrome in Koreans: a genetic association study. Clin Immunol. 2019;207:79\u201386.","journal-title":"Clin Immunol"},{"key":"2040_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ajhg.2008.10.006","volume":"83","author":"TL Yang","year":"2008","unstructured":"Yang TL, Chen XD, Guo Y, Lei SF, Wang JT, Zhou Q, et al. Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. Am J Hum Genet. 2008;83:663\u201374.","journal-title":"Am J Hum Genet"},{"key":"2040_CR24","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41416-019-0722-0","volume":"122","author":"EP Allain","year":"2020","unstructured":"Allain EP, Rouleau M, Levesque E, Guillemette C. Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression. Br J Cancer. 2020;122:1277\u201387.","journal-title":"Br J Cancer"},{"key":"2040_CR25","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1021\/bi002607y","volume":"40","author":"E Levesque","year":"2001","unstructured":"Levesque E, Turgeon D, Carrier JS, Montminy V, Beaulieu M, Belanger A. Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry. 2001;40:3869\u201381.","journal-title":"Biochemistry"},{"key":"2040_CR26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/eci.12037","volume":"43","author":"L Ekstrom","year":"2013","unstructured":"Ekstrom L, Cevenini L, Michelini E, Schulze J, Thorngren JO, Belanger A, et al. Testosterone challenge and androgen receptor activity in relation to UGT2B17 genotypes. Eur J Clin Invest. 2013;43:248\u201355.","journal-title":"Eur J Clin Invest"},{"key":"2040_CR27","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1210\/jc.2008-1984","volume":"94","author":"A Juul","year":"2009","unstructured":"Juul A, Sorensen K, Aksglaede L, Garn I, Rajpert-De Meyts E, Hullstein I, et al. A common deletion in the uridine diphosphate glucuronyltransferase (UGT) 2B17 gene is a strong determinant of androgen excretion in healthy pubertal boys. J Clin Endocrinol Metab. 2009;94:1005\u201311.","journal-title":"J Clin Endocrinol Metab"},{"key":"2040_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fendo.2014.00050","volume":"5","author":"JJ Schulze","year":"2014","unstructured":"Schulze JJ, Mullen JE, Berglund Lindgren E, Ericsson M, Ekstrom L, Hirschberg AL. The impact of genetics and hormonal contraceptives on the steroid profile in female athletes. Front Endocrinol. 2014;5:50.","journal-title":"Front Endocrinol"},{"key":"2040_CR29","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/dta.1841","volume":"7","author":"E Strahm","year":"2015","unstructured":"Strahm E, Mullen JE, Garevik N, Ericsson M, Schulze JJ, Rane A, et al. Dose-dependent testosterone sensitivity of the steroidal passport and GC-C-IRMS analysis in relation to the UGT2B17 deletion polymorphism. Drug Test Anal. 2015;7:1063\u201370.","journal-title":"Drug Test Anal"},{"key":"2040_CR30","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1530\/EC-18-0080","volume":"7","author":"A Mouritsen","year":"2018","unstructured":"Mouritsen A, Busch AS, Aksglaede L, Rajpert-De Meyts E, Juul A. Deletion in the uridine diphosphate glucuronyltransferase 2B17 gene is associated with delayed pubarche in healthy boys. Endocr Connect. 2018;7:460\u20135.","journal-title":"Endocr Connect"},{"key":"2040_CR31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijgo.2009.12.013","volume":"109","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Dai Y, Tu Z, Li Q, Wang L, Zhang L. Array-CGH detection of UGT2B28 gene deletion in a girl with primary amenorrhea and hyperandrogenism. Int J Gynaecol Obstet. 2010;109:164\u20136.","journal-title":"Int J Gynaecol Obstet"},{"key":"2040_CR32","first-page":"271","volume":"38","author":"JF Fahrmann","year":"2017","unstructured":"Fahrmann JF, Grapov DD, Wanichthanarak K, DeFelice BC, Salemi MR, Rom WN, et al. Integrated metabolomics and proteomics highlight altered nicotinamide- and polyamine pathways in lung adenocarcinoma. Carcinogenesis. 2017;38:271\u201380.","journal-title":"Carcinogenesis"},{"key":"2040_CR33","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1021\/pr401106h","volume":"13","author":"AK Kaushik","year":"2014","unstructured":"Kaushik AK, Vareed SK, Basu S, Putluri V, Putluri N, Panzitt K, et al. Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res. 2014;13:1088\u20131100.","journal-title":"J Proteome Res"},{"key":"2040_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07232-8","volume":"9","author":"SR Rosario","year":"2018","unstructured":"Rosario SR, Long MD, Affronti HC, Rowsam AM, Eng KH, Smiraglia DJ. Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas. Nat Commun. 2018;9:5330.","journal-title":"Nat Commun"},{"key":"2040_CR35","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1158\/1055-9965.EPI-18-1002","volume":"28","author":"E Levesque","year":"2019","unstructured":"Levesque E, Caron P, Lacombe L, Turcotte V, Simonyan D, Fradet Y, et al. A comprehensive analysis of steroid hormones and progression of localized high-risk prostate cancer. Cancer Epidemiol Biomark Prev. 2019;28:701\u20136.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2040_CR36","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1002\/humu.21054","volume":"30","author":"V Menard","year":"2009","unstructured":"Menard V, Eap O, Harvey M, Guillemette C, Levesque E. Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 and UGT2B28 and their associations with a UGT2B15 functional polymorphism. Hum Mutat. 2009;30:1310\u20139.","journal-title":"Hum Mutat"},{"key":"2040_CR37","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.tem.2003.10.005","volume":"14","author":"A Belanger","year":"2003","unstructured":"Belanger A, Pelletier G, Labrie F, Barbier O, Chouinard S. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab. 2003;14:473\u20139.","journal-title":"Trends Endocrinol Metab"},{"key":"2040_CR38","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1194\/jlr.D023036","volume":"53","author":"L Lofgren","year":"2012","unstructured":"Lofgren L, Stahlman M, Forsberg GB, Saarinen S, Nilsson R, Hansson GI. The BUME method: a novel automated chloroform-free 96-well total lipid extraction method for blood plasma. J Lipid Res. 2012;53:1690\u20131700.","journal-title":"J Lipid Res"},{"key":"2040_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.steroids.2015.07.009","volume":"104","author":"P Caron","year":"2015","unstructured":"Caron P, Turcotte V, Guillemette C. A chromatography\/tandem mass spectrometry method for the simultaneous profiling of ten endogenous steroids, including progesterone, adrenal precursors, androgens and estrogens, using low serum volume. Steroids. 2015;104:16\u201324.","journal-title":"Steroids"},{"key":"2040_CR40","doi-asserted-by":"publisher","first-page":"462228","DOI":"10.1016\/j.chroma.2021.462228","volume":"1650","author":"P Caron","year":"2021","unstructured":"Caron P, Turcotte V, Guillemette C. A quantitative analysis of total and free 11-oxygenated androgens and its application to human serum and plasma specimens using liquid-chromatography tandem mass spectrometry. J Chromatogr A. 2021;1650:462228.","journal-title":"J Chromatogr A"},{"key":"2040_CR41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41416-021-01376-z","volume":"125","author":"JP Emond","year":"2021","unstructured":"Emond JP, Lacombe L, Caron P, Turcotte V, Simonyan D, Aprikian A, et al. Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression. Br J Cancer. 2021;125:78\u201384.","journal-title":"Br J Cancer"},{"key":"2040_CR42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-4939-7592-1_13","volume":"1730","author":"TL Pedersen","year":"2018","unstructured":"Pedersen TL, Newman JW. Establishing and performing targeted multi-residue analysis for lipid mediators and fatty acids in small clinical plasma samples. Methods Mol Biol. 2018;1730:175\u2013212.","journal-title":"Methods Mol Biol"},{"key":"2040_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00606","author":"EP Allain","year":"2019","unstructured":"Allain EP, Rouleau M, Le T, Vanura K, Villeneuve L, Caron P, et al. Inactivation of prostaglandin E2 as a mechanism for UGT2B17-mediated adverse effects in chronic lymphocytic leukemia. Front Oncol. 2019. https:\/\/doi.org\/10.3389\/fonc.2019.00606","journal-title":"Front Oncol"},{"key":"2040_CR44","doi-asserted-by":"publisher","first-page":"22855","DOI":"10.1074\/jbc.271.37.22855","volume":"271","author":"M Beaulieu","year":"1996","unstructured":"Beaulieu M, Levesque E, Hum DW, Belanger A. Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids. J Biol Chem. 1996;271:22855\u201362.","journal-title":"J Biol Chem"},{"key":"2040_CR45","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1093\/hmg\/ddx266","volume":"26","author":"PS de Vries","year":"2017","unstructured":"de Vries PS, Yu B, Feofanova EV, Metcalf GA, Brown MR, Zeighami AL, et al. Whole-genome sequencing study of serum peptide levels: the Atherosclerosis Risk in Communities study. Hum Mol Genet. 2017;26:3442\u201350.","journal-title":"Hum Mol Genet"},{"key":"2040_CR46","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3109\/1354750X.2013.787544","volume":"18","author":"E Kashuba","year":"2013","unstructured":"Kashuba E, Bailey J, Allsup D, Cawkwell L. The kinin-kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers. Biomarkers. 2013;18:279\u201396.","journal-title":"Biomarkers"},{"key":"2040_CR47","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/ijc.30903","volume":"141","author":"HM Lin","year":"2017","unstructured":"Lin HM, Mahon KL, Weir JM, Mundra PA, Spielman C, Briscoe K, et al. A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer. Int J Cancer. 2017;141:2112\u201320.","journal-title":"Int J Cancer"},{"key":"2040_CR48","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41391-021-00338-z","volume":"24","author":"HM Lin","year":"2021","unstructured":"Lin HM, Huynh K, Kohli M, Tan W, Azad AA, Yeung N, et al. Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24:860\u201370.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2040_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17645-z","volume":"11","author":"J Vykoukal","year":"2020","unstructured":"Vykoukal J, Fahrmann JF, Gregg JR, Tang Z, Basourakos S, Irajizad E, et al. Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. Nat Commun. 2020;11:4279.","journal-title":"Nat Commun"},{"key":"2040_CR50","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1210\/jc.2005-1643","volume":"91","author":"J Jakobsson","year":"2006","unstructured":"Jakobsson J, Ekstrom L, Inotsume N, Garle M, Lorentzon M, Ohlsson C, et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab. 2006;91:687\u201393.","journal-title":"J Clin Endocrinol Metab"},{"key":"2040_CR51","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1210\/er.2015-1036","volume":"36","author":"JW Mueller","year":"2015","unstructured":"Mueller JW, Gilligan LC, Idkowiak J, Arlt W, Foster PA. The regulation of steroid action by sulfation and desulfation. Endocr Rev. 2015;36:526\u201363.","journal-title":"Endocr Rev"},{"key":"2040_CR52","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41568-021-00388-4","volume":"21","author":"AJ Hoy","year":"2021","unstructured":"Hoy AJ, Nagarajan SR, Butler LM. Tumour fatty acid metabolism in the context of therapy resistance and obesity. Nat Rev Cancer. 2021;21:753\u201366.","journal-title":"Nat Rev Cancer"},{"key":"2040_CR53","doi-asserted-by":"publisher","first-page":"103625","DOI":"10.1016\/j.ebiom.2021.103625","volume":"72","author":"HM Lin","year":"2021","unstructured":"Lin HM, Mak B, Yeung N, Huynh K, Meikle TG, Mellett NA, et al. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. EBioMedicine. 2021;72:103625.","journal-title":"EBioMedicine"},{"key":"2040_CR54","doi-asserted-by":"publisher","first-page":"45190","DOI":"10.18632\/oncotarget.16775","volume":"8","author":"J Huang","year":"2017","unstructured":"Huang J, Mondul AM, Weinstein SJ, Karoly ED, Sampson JN, Albanes D. Prospective serum metabolomic profile of prostate cancer by size and extent of primary tumor. Oncotarget. 2017;8:45190\u20139.","journal-title":"Oncotarget"},{"key":"2040_CR55","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1091\/mbc.e03-12-0894","volume":"15","author":"R Pai","year":"2004","unstructured":"Pai R, Tarnawski AS, Tran T. Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness. Mol Biol Cell. 2004;15:2156\u201363.","journal-title":"Mol Biol Cell"},{"key":"2040_CR56","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1002\/pros.23088","volume":"75","author":"T Goto","year":"2015","unstructured":"Goto T, Terada N, Inoue T, Kobayashi T, Nakayama K, Okada Y, et al. Decreased expression of lysophosphatidylcholine (16:0\/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer. Prostate. 2015;75:1821\u201330.","journal-title":"Prostate"},{"key":"2040_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0552-3","volume":"14","author":"T Kuhn","year":"2016","unstructured":"Kuhn T, Floegel A, Sookthai D, Johnson T, Rolle-Kampczyk U, Otto W, et al. Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study. BMC Med. 2016;14:13.","journal-title":"BMC Med"},{"key":"2040_CR58","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fimmu.2018.00038","volume":"9","author":"V Chiurchiu","year":"2018","unstructured":"Chiurchiu V, Leuti A, Maccarrone M. Bioactive lipids and chronic inflammation: managing the fire within. Front Immunol. 2018;9:38.","journal-title":"Front Immunol"},{"key":"2040_CR59","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1124\/mol.115.098582","volume":"88","author":"Y Miyauchi","year":"2015","unstructured":"Miyauchi Y, Nagata K, Yamazoe Y, Mackenzie PI, Yamada H, Ishii Y. Suppression of cytochrome P450 3A4 function by UDP-glucuronosyltransferase 2B7 through a protein-protein interaction: cooperative roles of the cytosolic carboxyl-terminal domain and the luminal anchoring region. Mol Pharm. 2015;88:800\u201312.","journal-title":"Mol Pharm"},{"key":"2040_CR60","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fphar.2017.00023","volume":"8","author":"M Rouleau","year":"2017","unstructured":"Rouleau M, Audet-Delage Y, Desjardins S, Rouleau M, Girard-Bock C, Guillemette C. Endogenous protein interactome of human UDP-glucuronosyltransferases exposed by untargeted proteomics. Front Pharm. 2017;8:23.","journal-title":"Front Pharm"},{"key":"2040_CR61","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1158\/0008-5472.CAN-17-3752","volume":"78","author":"K Kolijn","year":"2018","unstructured":"Kolijn K, Verhoef EI, Smid M, Bottcher R, Jenster GW, Debets R, et al. Epithelial-mesenchymal transition in human prostate cancer demonstrates enhanced immune evasion marked by IDO1 expression. Cancer Res. 2018;78:4671\u20139.","journal-title":"Cancer Res"},{"key":"2040_CR62","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1021\/acs.jproteome.8b00803","volume":"18","author":"A Khan","year":"2019","unstructured":"Khan A, Choi SA, Na J, Pamungkas AD, Jung KJ, Jee SH, et al. Noninvasive serum metabolomic profiling reveals elevated kynurenine pathway\u2019s metabolites in humans with prostate cancer. J Proteome Res. 2019;18:1532\u201341.","journal-title":"J Proteome Res"},{"key":"2040_CR63","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/pros.22704","volume":"73","author":"JE McDunn","year":"2013","unstructured":"McDunn JE, Li Z, Adam KP, Neri BP, Wolfert RL, Milburn MV, et al. Metabolomic signatures of aggressive prostate cancer. Prostate. 2013;73:1547\u201360.","journal-title":"Prostate"},{"key":"2040_CR64","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/nature07762","volume":"457","author":"A Sreekumar","year":"2009","unstructured":"Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910\u20134.","journal-title":"Nature"},{"key":"2040_CR65","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1158\/1055-9965.EPI-14-0458","volume":"23","author":"EH Allott","year":"2014","unstructured":"Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, et al. Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. Cancer Epidemiol Biomark Prev. 2014;23:2349\u201356.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2040_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6418-2","volume":"19","author":"E Zoni","year":"2019","unstructured":"Zoni E, Minoli M, Bovet C, Wehrhan A, Piscuoglio S, Ng CKY, et al. Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification. BMC Cancer. 2019;19:1216.","journal-title":"BMC Cancer"},{"key":"2040_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1220-2","volume":"15","author":"A Mafune","year":"2015","unstructured":"Mafune A, Hama T, Suda T, Suzuki Y, Ikegami M, Sakanashi C, et al. Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations and relapse of head and neck carcinoma. BMC Cancer. 2015;15:205.","journal-title":"BMC Cancer"},{"key":"2040_CR68","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/FPC.0000000000000135","volume":"25","author":"AZ Zhu","year":"2015","unstructured":"Zhu AZ, Cox LS, Ahluwalia JS, Renner CC, Hatsukami DK, Benowitz NL, et al. Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males. Pharmacogenet Genomics. 2015;25:263\u20139.","journal-title":"Pharmacogenet Genomics"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02040-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02040-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02040-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T14:06:29Z","timestamp":1675951589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02040-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1,19]]}},"alternative-id":["2040"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-02040-w","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was carried out in accordance with the Declaration of Helsinki. Patients provided informed consent before surgery, and the study was approved by local ethical research committees and CHUQc-UL #2012-362.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}